The central question in atopic dermatitis care has shifted from whether to use a biologic to which one, and Raj Chovatiya, MD, PhD, addresses that selection problem directly in a new HCPLive interview on biologic choice in moderate-to-severe disease.

Atopic dermatitis (chronic eczema driven by type 2 immune inflammation) now has multiple approved biologic options, and head-to-head comparative data remain scarce. That absence shapes the entire conversation. Chovatiya, a dermatologist and clinical investigator known for his work on inflammatory skin disease, walks through the practical reasoning clinicians apply when the evidence does not hand them a single answer.

What drives the choice?

Without comparative trials, selection rests on the factors clinicians can observe: patient phenotype, prior treatment response, comorbidities such as asthma or allergic rhinitis, and administration preferences. Each biologic targets a distinct point in the type 2 inflammatory cascade — interleukin (immune-signaling protein) pathways such as IL-4, IL-13, and IL-31 among them — and mechanistic differences plausibly matter for individual patients.

The interview format does not present new trial results. It is an expert commentary piece, and readers should weigh it accordingly. What it offers is a framework, not efficacy data; no PASI (Psoriasis Area and Severity Index, repurposed for eczema scoring) or EASI (Eczema Area and Severity Index) figures accompany the discussion.

Why this matters now

The biologic pipeline in atopic dermatitis has expanded rapidly, and each approval adds optionality while complicating the decision. Payers increasingly demand justification for one agent over another, and clinicians cannot always anchor that justification in randomized comparisons. Chovatiya's commentary speaks to that gap.

Notably absent from the discussion, at least as framed by its title, is any mention of cost, prior authorization mechanics, or payer coverage — practical constraints that often decide the question before mechanism does. Whether the interview addresses them in full is worth checking in the original segment.

The honest bottom line

Expert opinion fills the space where comparative evidence has not yet arrived. That is useful, and it is also the limit. Until head-to-head trials in atopic dermatitis biologics report, selection will remain a judgment exercise refined at the bedside rather than settled in the literature — a point interviews like this one implicitly concede.